Physician profile
Nerlyn Cooper
NPI 1760017933
$4,076.77
in general payments reported to CMS, 2019-2025
22 companies · $835 in 2025
The $835 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $913 · 2022: $1,279 · 2023: $174 · 2024: $876 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $772.58 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $638.17 | 2022-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $469.52 | 2021-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $351.58 | 2024-2025 | Omnipod |
| Amgen INC. | $306.18 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $228.22 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.61 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $192.25 | 2021-2024 | |
| Abbvie INC. | $129.49 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $118.63 | 2022-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $117.85 | 2025 | Korlym |
| Amarin Pharma, INC. | $102.23 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $98.57 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $63.89 | 2021 | |
| Cequr Corporation | $53.56 | 2024 | Cequr Simplicity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.58 | 2022 | |
| Radius Health, INC. | $42.27 | 2022 | |
| Merck Sharp & Dohme LLC | $32.34 | 2021-2022 | |
| Medtronic, INC. | $24.55 | 2024 | Minimed 780g |
| Recordati_rare_diseases_inc. | $23.25 | 2022 | |
| Averitas Pharma INC. | $22.94 | 2023 | Qutenza |
| Esperion Therapeutics, INC. | $15.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nerlyn Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.